Table VI.

Antibody response to SARS-CoV-2 vaccine in predominant antibody deficiency patients by secondary immunosuppression

Variable	Anti-spike antibody, U/mL (geometric mean [95% confidence interval])	P	Anti-spike antibody, <100 U/mL (odds ratio [95% confidence interval])	P
Immune suppression (ever)
Yes	142 (55.3-367.8)
No	123.9 (9.9-1,543)	.91	0.35 (0.08-1.6)	.18
Immune suppression (≤1 mo before)
Yes	30.1 (5.6-162.4)
No	276.5 (104.9-728.9)	.02	1.5 (0.5-4.5)	.45
Immune suppression (≤1 mo after)
Yes	39.1 (6-253.1)
No	258.4 (87.1-766.3)	.07	1.4 (0.4-4.6)	.61
B cell depletion therapy
Ever
Yes	11.6 (1.3-94.7)
No	289.8 (121.9-688.7)	<.01	5.5 (1.5-20.4)	.01
Recent (≤6 mo before to ≤1 mo after)
Yes	0.67 (0.39-1.1)
No	308.8 (140.9-676.7)	<.01	36.4 (1.7-791.9)	.02